MYRIAD GENETICS INC (MYGN)
$3.16-$0.02 (-0.63%) Today
Lee Nisley Newcomer - DirectorMyriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 1 | 15,000 | $67K |
| Grant or award | 11 | 738,039 | |
| Tax withholding / forfeiture | 1 | 8,761 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
54 Form 4 filings on record, the earliest from Oct 10, 2024, newest first. Filing history page 2 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Shereen Solaiman - Officer | Tax withholding / forfeiture | Common Stock | 1,675 | $4.61 | $8K | |
| S. Louise Phanstiel - Director | Open-market purchase | Common Stock | 6,100 | $4.74 | $29K | |
| S. Louise Phanstiel - Director | Open-market purchase | Common Stock | 50,407 | $4.80 | $242K | |
| S. Louise Phanstiel - Director | Open-market purchase | Common Stock | 48,000 | $4.66 | $224K | |
| Benjamin Richard Wheeler - Officer | Grant or award | Common Stock | 4,994 | $0.00 | - | |
| Mark Verratti - Officer | Grant or award | Common Stock | 32,810 | $0.00 | - | |
| Dale Muzzey - Officer | Grant or award | Common Stock | 23,697 | $0.00 | - | |
| Kevin Richard Haas - Officer | Grant or award | Common Stock | 23,697 | $0.00 | - | |
| Margaret Ancona - Officer | Tax withholding / forfeiture | Common Stock | 958 | $7.77 | $7K | |
| Mark Verratti - Officer | Tax withholding / forfeiture | Common Stock | 1,085 | $7.77 | $8K | |
| Benjamin Richard Wheeler - Officer | Tax withholding / forfeiture | Common Stock | 2,559 | $7.77 | $20K | |
| Natalie Munk - Officer | Tax withholding / forfeiture | Common Stock | 962 | $7.77 | $7K | |
| Jennifer Lynne Fox - Officer | Tax withholding / forfeiture | Common Stock | 4,435 | $6.80 | $30K | |
| Benjamin Richard Wheeler - Officer | Grant or award | Common Stock | 60,000 | $0.00 | - | |
| Paul Bisaro - Director | Grant or award | Common Stock | 49,796 | $0.00 | - | |
| Samraat S. Raha - Officer | Tax withholding / forfeiture | Common Stock | 29,578 | $14.51 | $429K | |
| Mark Steven Davis - Director | Grant or award | Common Stock | 22,816 | $0.00 | - | |
| Samraat S. Raha - Officer | Grant or award | Common Stock | 1,118 | $13.83 | $15K | |
| Paul J. Diaz - Officer | Open-market sale | Common Stock | 15,000 | $22.93 | $344K | |
| Mark Verratti - Officer | Tax withholding / forfeiture | Common Stock | 3,359 | $24.37 | $82K | |
| Mark Verratti - Officer | Tax withholding / forfeiture | Common Stock | 5,004 | $24.37 | $122K | |
| Kevin Richard Haas - Officer | Tax withholding / forfeiture | Common Stock | 2,515 | $24.37 | $61K | |
| Dale Muzzey - Officer | Tax withholding / forfeiture | Common Stock | 452 | $24.37 | $11K |
This is as far as the anonymous view goes. Create a free account for all 54 MYGN filings on record.
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| - | - | - | - | View on EDGAR |
MYRIAD GENETICS INC (MYGN) had 14 insider filings in the last 90 days, with the most recent on 2026-08-17. The full record for MYGN runs to 54 Form 4 filings, the earliest from 2024-10-10. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of MYGN were filed in the last 90 days. 5 purchases are on record for this company.
1 insider sale of MYGN was filed in the last 90 days, totaling $67K.
This page tracks MYGN Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add MYGN to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
